219 related articles for article (PubMed ID: 22071119)
1. Piperazine compounds as drugs of abuse.
Arbo MD; Bastos ML; Carmo HF
Drug Alcohol Depend; 2012 May; 122(3):174-85. PubMed ID: 22071119
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of designer drugs of abuse.
Staack RF; Maurer HH
Curr Drug Metab; 2005 Jun; 6(3):259-74. PubMed ID: 15975043
[TBL] [Abstract][Full Text] [Related]
3. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis.
Maurer HH; Kraemer T; Springer D; Staack RF
Ther Drug Monit; 2004 Apr; 26(2):127-31. PubMed ID: 15228152
[TBL] [Abstract][Full Text] [Related]
4. Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment.
Arbo MD; Silva R; Barbosa DJ; da Silva DD; Rossato LG; Bastos Mde L; Carmo H
Toxicol Lett; 2014 Aug; 229(1):178-89. PubMed ID: 24968061
[TBL] [Abstract][Full Text] [Related]
5. Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry.
Peters FT; Schaefer S; Staack RF; Kraemer T; Maurer HH
J Mass Spectrom; 2003 Jun; 38(6):659-76. PubMed ID: 12827635
[TBL] [Abstract][Full Text] [Related]
6. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples.
Dickson AJ; Vorce SP; Holler JM; Lyons TP
J Anal Toxicol; 2010 Oct; 34(8):464-9. PubMed ID: 21819791
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of piperazine designer drugs: Comparison of different in vitro models.
Dias-da-Silva D; Arbo MD; Valente MJ; Bastos ML; Carmo H
Toxicol In Vitro; 2015 Aug; 29(5):987-96. PubMed ID: 25863214
[TBL] [Abstract][Full Text] [Related]
8. Methylone and mCPP, two new drugs of abuse?
Bossong MG; Van Dijk JP; Niesink RJ
Addict Biol; 2005 Dec; 10(4):321-3. PubMed ID: 16318952
[TBL] [Abstract][Full Text] [Related]
9. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain.
Baumann MH; Clark RD; Budzynski AG; Partilla JS; Blough BE; Rothman RB
Ann N Y Acad Sci; 2004 Oct; 1025():189-97. PubMed ID: 15542717
[TBL] [Abstract][Full Text] [Related]
10. Piperazine designer drugs elicit toxicity in the alternative in vivo model Caenorhabditis elegans.
Souto C; Göethel G; Peruzzi CP; Cestonaro LV; Garcia I; Ávila DS; Eifler-Lima V; Carmo H; Bastos ML; Garcia SC; Arbo MD
J Appl Toxicol; 2020 Mar; 40(3):363-372. PubMed ID: 31755144
[TBL] [Abstract][Full Text] [Related]
11. Clinical toxicology of newer recreational drugs.
Hill SL; Thomas SH
Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
[TBL] [Abstract][Full Text] [Related]
12. Chemistry, pharmacology, and metabolism of emerging drugs of abuse.
Maurer HH
Ther Drug Monit; 2010 Oct; 32(5):544-9. PubMed ID: 20683389
[TBL] [Abstract][Full Text] [Related]
13. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine.
Tsutsumi H; Katagi M; Miki A; Shima N; Kamata T; Nishikawa M; Nakajima K; Tsuchihashi H
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 May; 819(2):315-22. PubMed ID: 15833296
[TBL] [Abstract][Full Text] [Related]
14. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine.
Schep LJ; Slaughter RJ; Vale JA; Beasley DM; Gee P
Clin Toxicol (Phila); 2011 Mar; 49(3):131-41. PubMed ID: 21495881
[TBL] [Abstract][Full Text] [Related]
15. mCPP: an undesired addition to the ecstasy market.
Bossong MG; Brunt TM; Van Dijk JP; Rigter SM; Hoek J; Goldschmidt HM; Niesink RJ
J Psychopharmacol; 2010 Sep; 24(9):1395-401. PubMed ID: 19304863
[TBL] [Abstract][Full Text] [Related]
16. [1-benzylpiperazine (BZP) and 1-(3-trifluorométhylphényl)pipérazine (TFMPP): emergence of two agents which lead to misuse].
Lecompte Y; Roussel O; Perrin M
Ann Pharm Fr; 2008 Mar; 66(2):85-91. PubMed ID: 18570904
[TBL] [Abstract][Full Text] [Related]
17. Rave drugs: pharmacological considerations.
Klein M; Kramer F
AANA J; 2004 Feb; 72(1):61-7. PubMed ID: 15098519
[TBL] [Abstract][Full Text] [Related]
18. ["Legal highs" from the German internet--"bath salt drugs" on the rise].
Musshoff F; Hottmann L; Hess C; Madea B
Arch Kriminol; 2013; 232(3-4):91-103. PubMed ID: 24358620
[TBL] [Abstract][Full Text] [Related]
19. GHB and synthetic cathinones: clinical effects and potential consequences.
Karila L; Reynaud M
Drug Test Anal; 2011 Sep; 3(9):552-9. PubMed ID: 21960540
[TBL] [Abstract][Full Text] [Related]
20. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market.
de Boer D; Bosman IJ; Hidvégi E; Manzoni C; Benkö AA; dos Reys LJ; Maes RA
Forensic Sci Int; 2001 Sep; 121(1-2):47-56. PubMed ID: 11516887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
